葵花药业：关于盐酸非索非那定口服混悬液获得药品注册证书的公告

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its oral suspension of Fexofenadine Hydrochloride [2] Group 2 - The approval of the drug registration indicates a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry, particularly in allergy treatment [2] - The registration could lead to increased revenue opportunities for Kew Flower Pharmaceutical as it introduces the new product to the market [2]